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RESEARCH ARTICLE
Selective inhibition of N-linked glycosylation impairs receptor
tyrosine kinase processing
Elsenoor Klaver1, Peng Zhao1, Melanie May2, Heather Flanagan-Steet2, Hudson H. Freeze3, Reid Gilmore4,
Lance Wells1, Joseph Contessa5,*,‡ and Richard Steet1,2,*,‡
ABSTRACT
Global inhibition of N-linked glycosylation broadly reduces glycan
occupancy on glycoproteins, but identifying how this inhibition
functionally impacts specific glycoproteins is challenging. This limits
our understanding of pathogenesis in the congenital disorders of
glycosylation (CDG).We used selective exo-enzymatic labeling of cells
deficient in the two catalytic subunits of oligosaccharyltransferase –
STT3A and STT3B – to monitor the presence and glycosylation status
of cell surface glycoproteins. We show reduced abundance of two
canonical tyrosine receptor kinases – the insulin receptor and insulin-
like growth factor 1 receptor (IGF-1R) – at the cell surface inSTT3A-null
cells, due to decreased N-linked glycan site occupancy and proteolytic
processing in combination with increased endoplasmic reticulum
localization. Providing cDNA for Golgi-resident proprotein convertase
subtilisin/kexin type 5a (PCSK5a) and furin cDNA to wild-type and
mutant cells produced under-glycosylated forms of PCSK5a, but not
furin, in cells lacking STT3A. Reduced glycosylation of PCSK5a in
STT3A-null cells or cells treated with the oligosaccharyltransferase
inhibitorNGI-1 correspondedwith failure to rescue receptor processing,
implying that alterations in the glycosylation of this convertase
have functional consequences. Collectively, our findings show that
STT3A-dependent inhibition of N-linked glycosylation on receptor
tyrosine kinases and their convertases combines to impair receptor
processing and surface localization. These results provide new insight
into CDG pathogenesis and highlight how the surface abundance of
some glycoproteins can be dually impacted by abnormal glycosylation.
KEY WORDS: Congenital, Convertase, Glycoproteins,
Oligosaccharyltransferase, Furin, PCSK5, INSR, IGF-1R,
Protein processing, STT3B
INTRODUCTION
Glycosylation on cell surface receptors regulates their activity,
stability and interaction with ligands (Rudd et al., 2001; Shao and
Haltiwanger, 2003; Boscher et al., 2011; Takahashi et al., 2016).
Numerous studies have demonstrated the direct effects of specific
glycosyltransferases on receptor function in the context of common
disease states, including cancer and diabetes (Ohtsubo and Marth,
2006). In contrast, much less is known about how global defects in
glycosylation, such as those found in many congenital disorders of
glycosylation (CDG), alter the maturation, stability and function of
receptors and other cell surface glycoproteins. Defining these
effects will provide clues towards the complex and multisystem
pathogenesis of CDG and has added value in understanding how
small-molecule modulation of glycosylation might be harnessed for
the treatment of more common diseases.
Asparagine-linked glycosylation is initiated through the
biosynthesis of a 14-sugar lipid-linked oligosaccharide (LLO)
precursor on the cytosolic and luminal sides of the endoplasmic
reticulum (ER). The ER-localized oligosaccharyltransferase (OST)
complex is responsible for the transfer of the LLO precursor to
nascent polypeptides in the ER lumen (Kelleher and Gilmore,
2006). The two metazoan OST complexes contain one of two
catalytic subunits, STT3A or STT3B, five shared subunits plus
complex-specific accessory subunits that impact glycan-acceptor-
site recognition (Kelleher et al., 2003; Cherepanova et al., 2016).
STT3A has been demonstrated to carry out the co-translational
N-linked glycosylation of nascent proteins as they enter the ER
lumen, whereas STT3B is responsible for post-translational
N-linked glycosylation of substrates, including the transfer of
oligosaccharide to extreme C-terminal sites and to regions proximal
to disulfide bridges (Ruiz-Canada et al., 2009; Shrimal and
Gilmore, 2013; Shrimal et al., 2013b). Two new CDG types
caused by mutations in STT3A and STT3Bwere described recently,
indicating that optimal function of both subunits is required in
humans despite compensation in their function on a cellular level
(Shrimal et al., 2013a; Cherepanova and Gilmore, 2016).
Prior studies using an inhibitor of STT3 function (NGI-1)
demonstrated that receptor tyrosine kinases such as epidermal
growth factor receptor (EGFR) are strongly sensitive to blockade in
the N-glycosylation pathway, reducing cell surface localization and
signaling of the EGFR glycoprotein, and selectively arresting
proliferation in cell lines that are dependent on EGFR for survival
(Contessa et al., 2008; Lopez-Sambrooks et al., 2016; Baro et al.,
2019). As all receptor tyrosine kinases are N-glycosylated, it is
likely that loss of OST function will functionally impact other
receptors in addition to EGFR, as well as different cell surface
glycoproteins. Impaired N-linked glycosylation can in theory
directly impact receptors on many levels, including their folding
and cell surface stability, but also by indirectly impacting the
enzymes and proteins involved in the proteolytic maturation and
recycling of the receptors. Processing of many receptors is carried
out by proprotein convertases, such as furin and PCSK5. These
endoproteases typically reside in the trans-Golgi network and
convert large inactive receptors into their bioactive mature forms.Received 7 March 2019; Accepted 8 May 2019
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Using selective exo-enzymatic labeling (SEEL) of cells deficient in
each of the OST catalytic subunits, we identified reduced abundance
of several glycoproteins, including the insulin receptor (INSR) and
IGF-1R, at the cell surface in STT3A-null cells. The reduction of these
receptors at the cell surface corresponded with decreases in the
occupancy of their N-linked glycans and ER localization, and a
drastic reduction in their proteolytic maturation.We further identified
the proprotein convertase PCSK5 as another STT3A substrate and
show that overexpression of furin but not PCSK5a in STT3A-null
cells is capable of rescuing the impaired processing of both INSR
and IGF-1R. Acute inhibition of N-glycosylation using NGI-1
recapitulated the receptor glycosylation and processing defects, and
indicated that the functional consequences of this pharmacological
inhibition may extend to the function of both PCSK5a and furin.
These findings uncover a mechanism whereby STT3A-specific
defects in the N-glycosylation of receptor tyrosine kinases and
certain convertases that process them combine to limit cell surface
availability of the mature receptors. The implications of this discovery
towards CDG pathogenesis and the use of N-glycosylation
inhibitors for cancer therapy are considered.
RESULTS
SEEL-based proteomics identifies reduced cell surface
expression of receptor tyrosine kinases in STT3A-null cells
Our prior work established SEEL-based proteomics as a highly
effectiveway to assess cell surface glycoprotein abundance in cells
(Sun et al., 2016; Yu et al., 2016). Wild-type (WT), STT3A-null
and STT3B-null human embryonic kidney (HEK) cells were
subjected to SEEL-based proteomics using ST6Gal1 in order to
investigate how selective loss of N-glycan occupancy affects the
abundance of cell surface glycoproteins. Unlike complementary
approaches such as SILAC (stable isotope labeling by/with amino
acids in cell culture)-based proteomics to gauge N-glycan site
occupancy, SEEL-based proteomics has the added advantage of
specifically tracking the abundance of glycoproteins at the plasma
membrane in light of the membrane impermeability of both the
sialyltransferase and the biotin-modified nucleotide-sugar donor.
As shown in Fig. 1A, SEEL using ST6Gal1 labels several major
glycoproteins inWTHEK cells, some of which are shifted lower in
STT3A-null cells. No obvious effects on mobility were detected
among the major labeled glycoproteins in STT3B-null cells.
WT HEK cells were also treated with the inhibitor NGI-1 to
gauge the effects of acute blockade of OST function. Nearly all the
major labeled glycoproteins in NGI-1-treated cells were shifted
down, demonstratingmore robust effects on these proteinswhenOST
function is acutely inhibited. This likely reflects the ability of NGI-1
to target both STT3A and STT3B (Lopez-Sambrooks et al., 2016).
Following SEEL and immunoprecipitation, labeled glycoproteins
were subjected to proteomic analysis and assigned proteins quantified
by spectral counts in two separate runs (Table S1; only the 10 µM
NGI-1 treatment was used for quantification in the two runs). The
abundance of multiple glycoproteins was altered in the mutant and
NGI-treated cells, including that of several receptors, cell adhesion
molecules and transporters (Fig. 1B). Most notably in the STT3B
mutants was SLC2A1, or the glucose transporter GLUT1 that
bears a single N-glycan. Among the most affected receptors in the
STT3A-null cells were the receptor tyrosine kinases INSR and
IGF-1R. The levels of both receptors were also strongly reduced at
the cell surface of NGI-1-treated HEK cells. We chose to focus on
INSR and IGF-1R in light of the isoform specificity on cell surface
localization and our prior work on the effects of N-glycosylation
inhibition on this class of receptors.
INSR and IGF-1R exhibit decreases in N-glycan site
occupancy and greatly reduce proteolytic processing in
STT3A-null cells
A reduction in SEEL labeling has two possible explanations: (1) cell
surface expression of the protein is lower, or (2) the protein now
lacks glycans that can be modified by the SEEL procedure. The
reduced level of these receptors at the cell surface could arise due to
decreased expression of the receptors, impaired folding or transport
due to loss of N-glycans, or other indirect effects on enzymes or
proteins that process their proprotein forms to mature receptor
subunits. We investigated these potential mechanisms by first
performing western blotting for INSR and IGF-1R in WT,
STT3A-null and STT3B-null cells (Fig. 2A). Loss of N-glycans on
the receptors can be estimated by increased electrophoretic mobility
of the proteins, and any effects on receptor processing are gauged by
quantifying the relative level of pro-receptor and mature subunit
present. In both WT HEK and STT3B-null cells, both receptors
are largely present in the mature form (Fig. 2A). By contrast,
STT3A-null cells show greatly reduced proteolytic processing of
these receptors, with the majority of the protein (IGF-1R 71±6.9%,
INSR 87.6±1.0%; means±s.e.m.) remaining in the proprotein form
(Fig. 2B). A shift in molecular mass was also observed for these
receptors in STT3A-null cells, suggestive of the loss of some of their
N-glycans. A receptor processing defect in IGF-1R and INSR was
observed in LoVo cells, a cancer cell line reported to lack expression
of the proprotein convertase furin, although no obvious decreases in
the occupancy of N-glycans was noted in these cells. Unlike either
Fig. 1. SEEL-based proteomics identifies reduced cell surface expression of receptor tyrosine kinases in STT3A-null cells. (A) Representative
western blot using an anti-biotin antibody from four biological replicates of biotin-labeled glycoproteins following SEEL with ST6Gal1 in WT, STT3A-null (ΔA),
STT3B-null (ΔB) and 10 µM NGI-1-treated HEK cells. (B) Heat map overview of all glycoproteins with 2-fold or more reduction in abundance after SEEL
proteomics in STT3A-null, STT3B-null and 10 µM NGI-1-treated HEK cells compared to WT. Average of two proteomics runs.
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of the STT3 mutants, LoVo cells also exhibit a decrease in the
processing of the Met receptor.
The pro-forms of IGF-1R and INSR localize to the ER before they
move to the Golgi upon successful folding and are processed by
proprotein convertases that reside in the trans-Golgi network, such as
furin (Forsayeth et al., 1986; Bass et al., 1998). Lysates were treated
in the absence or presence of the glycosidases Endo H and PNGase F
to determine whether these receptors transited through the Golgi (the
N-glycans would be Endo-H resistant) or still resided in the ER (the
N-glycans would be Endo-H sensitive) (Fig. 2C). These results
demonstrated that the pro-form of both receptors was Endo-H
sensitive in the STT3A-null cells, indicative of a pre-Golgi/ER
localization, whereas the mature subunits predominantly seen in WT
and STT3B-null cells had N-glycans that were mostly Endo-H
resistant, consistent with transport through the cis-Golgi and
processing of the N-glycans to complex-type structures. To gain a
clearer picture of the extent of reduced glycosylation on INSR, lysates
were resolved on a 6% gel, providing more-definitive evidence of the
loss of multiple N-glycans (Fig. 2D). Next, we looked at whether the
lack of processing corresponded with a decrease in the ability of
IGF-1R to bind ligand and autophosphorylate its β-subunit. WT and
mutant HEK293were stimulated with recombinant IGF1 andwestern
blot analysis using an anti-phospho-IGF-1R antibody was performed
(Fig. 2E). These data clearly show a reduction in IGF-1R activation in
the STT3A-null cells that corresponds with the impairment in its
processing. Lastly, we performed immunostaining with an antibody
to IGF-1R in all four lines, confirming the intracellular localization of
this receptor in STT3A-null cells and the surface localization in the
Fig. 2. INSR and IGF-1R exhibit modestly decreased N-glycan occupancy but greatly reduced proteolytic processing in STT3A-null cells. (A) Western
blot analysis of IGF-1R, INSR and Met receptor in WT, STT3A-null (ΔA), STT3B-null (ΔB) and LoVo cells. β-actin was used a loading control. Blots are
representative of four individual experiments. (B) Quantification of the level of pro-receptor relative to the total amount of receptor (pro-receptor+mature receptor).
Average ratios from four separate experiments are shown; error bars represent s.e.m. One-way ANOVA analysis was used to determine statistical significance.
***P<0.001. (C) Western blot analysis of IGF-1R and INSR in untreated, Endo-Hf- and PNGase-F-treated cell lysates. (D) Western blot analysis of pro-INSR in
HEK WT, STT3A-null and STT3B-null cells. (E) Analysis of IGF-1R processing and phosphorylation following IGF-1 stimulation in HEK WT, STT3A-null and
STT3B-null cells. (F) IGF-1R (green) and DAPI (blue) immunostaining of HEK WT, STT3A-null, STT3B-null and LoVo cells. (G) Co-staining of IGF-1R with
calnexin (CNX) and ERGIC-53 in STT3A-null cells.
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other two lines (Fig. 2F). Co-staining experiments with IGF-1R
and markers of the ER (calnexin) and ERGIC (ERGIC-53) in the
STT3A-null cells revealed partial but not complete overlap with
calnexin and only slight overlap with ERGIC-53. Staining that did
not correspond with either marker was also observed, suggesting that
the unprocessed receptor is likely distributed in multiple pre-Golgi
compartments in these cells (Fig. 2G). These collective findings
indicate that the glycosylation and proteolytic processing of both
INSR and IGF-1R is impaired in STT3A-null cells due in part to
failure of these receptors to exit the ER. The lack of processing in the
STT3A-null cell is consistent with that observed in convertase-
deficient LoVo cells (Dubois et al., 1995; Lehmann et al., 1998;
Lissitzky et al., 2000). However, in LoVo cells, the receptor
pro-forms are still able to escape the ER and travel to the Golgi, as
evidenced by the Endo-H resistance of their N-glycans in this cell line
(Fig. 2C) and partial cell surface localization of IGF-1R (Fig. 2F).
Furin-like proprotein convertases process INSR and IGF-1R
in HEK cells
The reduction in receptor processing in the STT3A-null cells could
arise solely from failure of the receptors to escape the ER, as has been
demonstrated by earlier studies that show the function of specific
glycans in receptor folding and transport (Collier et al., 1993; Bass
et al., 1998; Hwang and Frost, 1999; Hwang et al., 2000). Reduced
processing can also arise due to a decrease in the activity of
the proprotein convertases that carry out receptor maturation within
the secretory apparatus. We first confirmed whether furin-like
convertases were responsible for processing INSR in WT and
mutant HEK cells by treating these cells with a general furin inhibitor
(Dec-RVKR) and determining the effects on receptor processing. As
shown in Fig. 3A, INSR processing was reduced in WT and
STT3B-null cells. The lack of a complete block likely reflects the
lower dose of inhibitor we used to avoid toxicity and attachment
problems seen at higher doses. The inhibitor had only a minor effect
in STT3A-null cells since the receptor is already largely unprocessed.
At concentrations used in this experiment, furin-like convertase
activity was strongly lowered by the inhibitor (Fig. 3B), supporting a
major role for these convertases in receptor processing in HEK cells.
Next, we investigated whether the glycans of pro-form INSR were
characteristic of Golgi modifications by treatingwith Dec-RVKR and
investigating the Endo-H sensitivity of INSR (Fig. 3C). Endo-H
treatment of WT and STT3B-null cells demonstrated that some but
not all of the receptor is sensitive to this glycosidase, indicating that
some of the receptor preform can still escape the ER upon convertase
inhibition. In contrast, the entire population of INSR was Endo-H
sensitive in STT3A-null cells, supporting its primary residence in
the ER in Dec-RVKR-treated cells. Transcript analysis on several
proprotein convertases was performed to determine which enzymes
are most abundantly expressed in HEK cells (Fig. 3D). These results
show that furin, PCSK5a, PCSK6 and PCSK7 are expressed in WT
cells, but PCSK5b and PCSK9 are not. Two of the expressed
convertases – furin and PCSK5a – are known to play a role in receptor
tyrosine kinase maturation (Dubois et al., 1995; Lehmann et al.,
1998; Logeat et al., 1998; Siegfried et al., 2003; Essalmani
et al., 2008; Susan-Resiga et al., 2011; Al Rifai et al., 2017;
Szumska et al., 2017), so we analyzed the transcript abundance of
these enzymes in the STT3 mutant HEK lines and LoVo cells.
Transcripts for both proteases were detected in the STT3 mutants
(Fig. 3E). Transcript abundance for both proteases wasmuch lower or
absent in LoVo cells, consistent with the established loss of this
convertase activity in these cells (Lehmann et al., 1998). PCSK5
transcript abundance was decreased in both STT3 HEK mutants. To
investigate whether the decreased expression corresponds with lower
convertase activity, global convertase activity was measured in cell
lysates using a furin substrate (Fig. 3F). The overall convertase
activity in STT3B-null cells was higher toWTHEK cells but lower in
both STT3A-null and NGI-1-treated HEK cells, suggesting that a
reduction in N-glycan occupancy by genetic or pharmacological
methods alters global convertase activity. The activity measured was
mostly due to furin-like convertases as the presence of a general furin
Fig. 3. Proprotein expression and activity are decreased in STT3A-null cells. (A) INSR western blot analysis of HEK WT, STT3A-null (ΔA) and STT3B-null
(ΔB) cells after treatment with PCSK inhibitor Dec-RVKR. (B) PCSK activity in HEK WT cells, with and without addition of Dec-RVKR. (C) Western blot analysis
of INSR in Dec-RVKR-treated cells, followed by Endo-Hf- or PNGase-F treatment of the cell lysates. (D) Quantitative PCR analysis of PCSKs in HEK cells.
(E) Quantitative PCR analysis of the transcript abundance of PCSK5a and furin in the different cell lines studied (average of technical duplicates from three
biological replicates). One-way ANOVA analysis was used to determine statistical significance. (F) Average total convertase activity of three biological
replicates towards a furin substrate in WT, mutant and NGI-1-treated HEK cells and in LoVo cells. One-way ANOVA analysis was done to determine
statistical significance. Error bars represent s.e.m. *P<0.05, **P<0.01, ***P<0.001.
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inhibitor was sufficient to inhibit over 95% of the activity detected in
all lysates (not shown). Global convertase activity in LoVo cells was
also decreased, to a similar level found in STT3A-null cells, in line
with the loss of furin expression in these cells. Whether this reduced
activity is a function of altered expression, maturation or stability of
one or more furin-like proteases could not be established but,
taken together, the above findings suggest that loss or inhibition of
STT3A impacts convertase activity. Reduced activity or function
may in turn compound the defects in receptor processing caused by
their ER retention.
Ectopically expressed PCSK5 is underglycosylated in STT3A-
null cells and fails to rescue the receptor-processing defects
We attempted to look at endogenous levels and electrophoretic
mobility of the two main convertases responsible for receptor
processing but were unsuccessful due to non-reactive commercial
antibodies and/or the inherent instability of these proteases
following zymogen activation. To overcome this limitation, we
chose instead to ectopically express FLAG-tagged forms of these
proteases in the cell lines studied. Expression clones of murine
furin and PCSK5a were obtained and transfected in the cells
followed by western blot for the tagged proteases, INSR and
IGF-1R to determine whether either protease could restore normal
receptor maturation. The murine and human convertases are
highly conserved with identical numbers and position of their
N-glycan sites. As shown in Fig. 4A, the tagged convertases
are readily detected in all four transfected cell lines, although
the electrophoretic mobility of PCSK5a was clearly increased in the
STT3A-null cells. In contrast, furin did not appear to be altered in the
STT3A mutant cells. Ectopic expression of both convertases in WT
HEK cells increased processing of the small amount of receptor
pro-forms. In STT3A-null cells, furin expression resulted in robust
Fig. 4. Ectopically expressed PCSK5a is underglycosylated in STT3A-null cells and fails to rescue the receptor-processing defects. (A) Representative
western blots in HEK and LoVo cells transfected with Flag-tagged murine constructs for PCSK5a and furin. (B) Quantification of the level of pro-receptor relative
to the total amount of receptor (pro-receptor+mature receptor). Average ratios from three (IGF-1R) or four (INSR) separate experiments are shown; error
bars represent s.e.m. One-way ANOVA analysis was used to determine statistical significance. **P<0.01, ***P<0.001. (C) INSR western blot of PCSK5a-
or furin-transfected HEK and LoVo cells, followed by Endo-Hf- or PNGase-F treatment of the cell lysates. (D) IGF-1R immunostaining of PCSK5a- and
furin-transfected and untransfected STT3A-null and LoVo cells.
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rescue of both the INSR- and IGF-1R-processing defect, whereas
only minimal rescue was observed following PCSK5a introduction.
The results are quantified in Fig. 4B. We then analyzed whether
rescue of INSR processing by expression of tagged furin or PCSK5a
resulted in a change in the localization of the pro- and mature forms
of the receptor. After furin and PCSK5a introduction, the upper
portion of mature INSR in STT3A-null cells is similar in its
glycosidase sensitivity to what was observed in untransfected cells.
However, there is another fraction of the mature form of the receptor
(the lower portion) that remains Endo-H sensitive (Fig. 4C). We
interpret this finding to reflect the processing of INSR in the early
secretory pathway by the convertases but failure of the mature form
of the receptor to reach the medial Golgi compartment and become
Endo-H sensitive. The action of furin on INSR in the early secretory
pathway was demonstrated in prior studies showing processing of
mutant receptors in the ER despite the primary localization of furin
in the trans-Golgi (Bass et al., 2000). As with the western blot
results on INSR, we observed nearly all the IGF-1R staining inside
the cells following convertase introduction into STT3A-null cells
despite the efficient rescue of processing by furin and partial
restoration by PCSK5a. Interestingly, the intracellular convertases
are able to rescue receptor processing in LoVo cells even though
much of the pro-form of IGF-1R can be found at the cell surface
(Fig. 4D). One possible explanation for this finding is that newly
synthesized receptor in the ER is processed in this compartment
and eventually replaces the surface-localized pro-form receptor
following the 48 h post-transfection period. The IGF-1R pro-form is
also found inside LoVo cells, and may provide a pool of protein
accessible to the overexpressed convertases in the ER.
Lack of rescue by PCSK5a in STT3A-null cells does not arise
due to differences in localization
To more closely examine the underglycosylation of the convertases,
cells were again transfected with expression constructs for furin
and PCSK5a, and cell lysates analyzed by western blot following
Endo-H or PNGase-F treatment. The results in Fig. 5A clearly
demonstrate the loss of N-glycans on PCSK5a when expressed in
STT3A-null cells (shown most clearly in the lower panel where the
different lines are compared side by side). The expressed enzyme
detected in these cells runs as a heterogeneous band from
100-110 kDa and appears to contain some protein that is likely
fully deglycosylated. Furin behaved similarly following transfection
in all three lines with regard to Endo-H sensitivity, indicating that
the convertase exists in a pre-Golgi compartment. We cannot rule
out that the two N-glycans of furin remain Endo-H sensitive despite
their transit through the Golgi. The Endo-H sensitivity of expressed
PCSK5a also suggests that the protein largely remains in the ER or
early Golgi. WT and STT3A-null cells expressing tagged-PCSK5a
and furin were immunostained with antibodies to the Myc tag and
the ER marker ERp29 (Fig. 5B). The results show that the
convertases have some overlap with ERp29 but also exist in other
non-Golgi compartments. The highest degree of colocalization was
observed between ERp29 and PCSK5a in the STT3A-null cells. It is
not clear whether overexpression of the tagged proteins saturated the
ability of specific intracellular chaperones or binding proteins to
carry the convertases to the trans-Golgi network or whether
overexpression impairs the initial steps in convertase maturation.
Nonetheless, PCSK5a rescues receptor processing in WT but not
completely in STT3A-null cells, despite having similar localization
and Endo-H sensitivity of their N-glycans. This difference argues
that the loss of N-glycan occupancy likely alters the activity or
zymogen activation of PCSK5a. It is possible, however, that the
modest difference in localization between PCSK5a and furin in the
STT3A-null cells is also a contributing factor.
NGI-1 treatment of transfectedHEK cells results in receptor-
processing defects and significant underglycosylation of
PCSK5
The results above suggest that aberrant PCSK5 glycosylation in
STT3A-null cells may contribute to IGF-1R- and INSR-processing
defects. We next investigated whether treatment of WT HEK cells
with NGI-1 would result in a similar effect on both convertase
glycosylation and receptor processing. NGI-1 causes sequon
skipping by the OST and reduces glycosylation of both STT3A-
and STT3B-dependent sites (Rinis et al., 2018). Western blots of
IGF-1R and INSR in either furin- or PCSK5a-transfected WT and
NGI-1-treated cells shows a receptor-processing defect for both
receptors (Fig. 6A). Unlike in STT3A-null cells, this processing
defect is also observed with the Met receptor, likely pointing to the
more robust effects of NGI-1 compared to the STT3A mutant.
Expression of PCSK5a in NGI-treated cells failed to rescue the
Fig. 5. Robust decreases in N-glycan occupancy on PCSK5a but not furin
observed in STT3A-null cells. (A) Representative western blot of three
separate experiments of HEK WT and STT3A-null (ΔA) cells transfected
with tagged murine constructs for PCSK5 and furin in untreated, Endo-Hf-
and PNGase-F-treated cell lysates. Lower panel gives a side-by-side
comparison of the electrophoretic mobility of transfected furin and PCSK5 in
the three HEK cell lines. (B) Myc and ERp29 co-immunostaining of PCSK5-
and furin-transfected HEK WT and STT3A-null cells. Representative images
are shown (n=3). Pearson colocalization coefficients were calculated from
15 different cell images from two different fields in the three separate
experiments. Means±s.d. are shown.
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processing of INSR or IGF-1R and, interestingly, furin was only
able to weakly restore processing in these treated cells (Fig. 6A,B).
Western blot analysis of the two expressed convertases in NGI-1-
treated cells shows a profound loss of N-glycosylation on PCSK5a
but also increased heterogeneity on furin that was not detected in the
STT3A-null cells (Fig. 6C). The effects on receptor processing do
not arise from NGI-1-induced changes in convertase expression
(Fig. 6D). These data suggest that PCSK5a and furin activity are
sensitive to loss of N-glycosylation following acute OST inhibition
with NGI-1 and show that pharmacological inhibition of the OST
also disrupts convertase glycosylation and activity, which
contributes to processing defects on both IGF-1R and INSR as
well as Met receptor.
Loss of specific N-glycans on PCSK5 and furin does not alter
activity and ability to rescue receptor processing in the ER
We next investigated whether removal of specific N-glycan sequons
on both PCSK5a and furin would impact their activity and ability to
restore receptor processing in the ER. Single N-sequon mutants for
the two convertases were generated by site-directed mutagenesis,
expressed in LoVo cells, and processing of both INSR and IGF-1R
was analyzed by western blot (Fig. 7). The anti-FLAG blots showed
the predicted increases in electrophoretic mobility following loss of
the N-glycan sites on each convertase. Surprisingly, the
overexpressed N-glycan mutants of each convertase are still able
to rescue receptor processing, even the double N-glycan mutant of
furin. For PCSK5a, it is likely that deletion of multiple N-glycan
sites is required to recapitulate the findings noted after expression of
PCSK5a in STT3A-null cells, based on the extent of the effects on
this enzyme in both STT3A-null and NGI-treated WT cells. Another
possibility is that loss of single N-glycan sites does affect activity
but that overexpression of these proteins results in sufficient residual
activity for receptor processing to still take place. Lastly, we cannot
rule out that glycosylation defects on other ER glycoproteins in the
STT3A-null and NGI-treated WT cells contributes to the failure of
transfected PCSK5a to rescue receptor processing.
DISCUSSION
Identifying how a reduction in the global N-glycosylation
machinery of the cell impacts the function of specific
Fig. 6. NGI-1 treatment of transfected HEK cells results in underglycosylation of both furin and PCSK5, leading tomore penetrant receptor-processing
defects. (A) Representative western blots of HEKWT and 10 µMNGI-1-treated cells transfected with Flag-tagged murine constructs for PCSK5a and furin (n=3).
(B) Quantification of the level of pro-receptor relative to the total amount of receptor (pro-receptor+mature receptor) of three biological replicates. Error bars
represent s.e.m. (C) Representative western blot from three separate experiments of HEK WT and NGI-1-treated cells transfected with Flag-tagged murine
constructs for PCSK5a and furin in untreated and PNGase-F-treated cell lysates. (D) Quantitative PCR analysis of the transcript abundance of PCSK5a and furin
in HEK WT and NGI-1-treated cells. **P<0.01, ***P<0.001.
Fig. 7. Site-directed mutagenesis in PCSKa N-glycan sites does not
affect rescue in LoVo cells. Site-directed mutagenesis was done on four
N-glycan sites of PCSK5a and two furin N-glycan sites. Representative Flag,
INSR and IGF-1R western blots of LoVo cells transfected withWT or N-glycan-
site-mutated constructs for PCSK5a and furin. β-actin was used as a loading
control. Blots are representative of three individual transfections.
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glycoproteins remains a significant challenge towards defining the
pathogenesis of CDGs. This challenge is embodied by the fact that
multiple glycoproteins may lose one or more N-glycans in the
context of many CDGs, but whether this loss is functionally relevant
is not always apparent. The analysis of individual proteins is
therefore warranted but choosing which proteins to focus on adds
another layer of complexity. In this study, we uncovered a defect in
the processing of two receptor tyrosine kinases in cells lacking the
OST subunit STT3A that arises due to loss of N-glycans on the
receptor themselves as well as altered glycosylation and activity of
the proprotein convertase PCSK5a. All of these proteins are highly
glycosylated, with INSR and IGF-1R bearing 19 and 11 potential
N-glycan sites, respectively, and PCSK5a and furin bearing 5 and 2
potential sites, respectively. SEEL labeling of the WT and STT3
mutant HEK cell lines proved useful in identifying a significant
reduction in both INSR and IGF-1R at the surface of the STT3A-null
cells, allowing us to prioritize targets that exhibit functional
consequences of decreased N-glycosylation – in this case,
reduced cell surface localization. Western blot analysis of these
receptors revealed near-normal steady-state levels, indicating that
the processing defect in these receptors is associated with their
failure to reach the cell surface. When OST function is more broadly
and acutely inhibited using NGI-1, the receptor-processing defects
encompass additional receptors such as Met, reflecting NGI-1-
dependent defects in Met-receptor glycosylation and possible
effects on multiple proprotein convertases.
Loss of N-glycosylation has been associated with defects in the
activation of other proprotein convertases such as PC1/3 and SKI-1
(Zandberg et al., 2011), supporting a role for specific N-glycans in
zymogen activation. The loss of activity following a reduction in N-
glycan occupancy in the STT3A-null cells and NGI-1-treated cells is
consistent with our measurement of global convertase activity
(Fig. 3F). More substantial effects on activity may in fact be masked
by the presence of another furin-like proprotein convertase that can
utilize the furin substrate. We were unfortunately not able to
monitor the glycosylation status of endogenous convertases to
determine the extent of their underglycosylation in the STT3A-null
cells. Nonetheless, our data align with a model whereby STT3A-
dependent effects on INSR and IGF-1R as well as PCSK5a cause ER
retention of the receptors and limit their processing in the ER when
PCSK5a is overexpressed. It is interesting to note that several other
glycoproteins with lower surface abundance in the STT3A-null cells,
such as many α-integrins, are known substrates for PCSK5a
(Lissitzky et al., 2000; Bergeron et al., 2003; Stawowy et al.,
2004), highlighting other examples where combined effects on
substrates and their convertases may be operational. One area of
future investigation will be to determine whether reduction of other
glycoproteins at the cell surface is due to direct effects on
glycosylation on the glycoprotein, secondary effects on convertase
function or a combination of the two.
The present findings shed important new light on the pathogenesis
of CDGs associated with OST defects. The recently described
STT3A-CDG manifests with microcephaly, developmental delay,
seizures, intellectual disability and gastrointestinal symptoms
(Shrimal et al., 2013a). These symptoms show significant overlap
with the diseases caused by mutations in INSR or IGF-1R, two
receptor tyrosine kinases that we have now shown to be
underglycosylated when STT3A function is compromised.
Mutations in both of these receptor tyrosine kinases are very rare,
with IGF-1R mutation being found almost exclusively as a
heterozygous mutation (Kruis et al., 2010; Wallborn et al., 2010;
Labarta et al., 2013). Patients with IGF-1R mutation show growth
retardation, microcephaly, feeding problems and mild intellectual
impairment (Ester et al., 2009;Walenkamp et al., 2013). Mutations in
INSR lead to Donohue syndrome, a rare autosomal dominant disease
that is hallmarked by low bodyweight, microcephaly, musclewasting
and excessive thick skin (Kirkwood et al., 2018). The similarity in
symptoms between INSR or IGF-1R mutation and STT3-CDG
symptoms indicate a possible role for these proteins in the
developmental pathogenesis of STT3A-CDG.
In the case of the receptor tyrosine kinases studied in this paper,
the loss of surface localization is caused in part by the reduction of
N-glycosylation on the receptors themselves. Nonetheless, the clear
underglycosylation of PCSK5a and its failure to rescue processing
when introduced in STT3A-null cells highlights an intriguing
consideration for CDG pathogenesis: some glycoproteins may be
indirectly affected by enzymes that are highly sensitive to abnormal
glycosylation. Indeed, due to its five N-linked glycosylation sites,
PCSK5a may serve as a sensor for abnormal glycosylation that can
rapidly reduce cellular protease activity. Likewise, there may be
cases where glycosylation of certain cell surface glycoproteins is
altered but without a functional consequence. This complexity
increases the challenge of unraveling pathogenic cascades in
disorders where glycosylation is globally disrupted and a wide
range of glycoprotein substrates are impacted. Studies to more fully
describe how inhibition of N-glycosylation affects the spectrum of
proprotein convertases in different tissues are ongoing and may lead
to the identification of more sensitive cell surface glycoproteins.
IGF-1R and INSR are homologous members of the receptor
tyrosine kinase superfamily of transmembrane glycoproteins, are
widely expressed in normal tissues, and are expressed at high levels
in malignant tumors. IGF-1R-stimulated downstream signaling, in
particular, has become a target for inhibition by small molecules or
receptor-specific antibodies in multiple tumor types. These
approaches for targeting IGF-1R are based upon the development
of successful therapies to other receptor tyrosine kinases such as
EGFR and ErBB2 (Chon et al., 2006; Mishra et al., 2018). PCSK5
expression is a predictor for tumor response to the EGFR tyrosine
kinase inhibitor erlotinib (Garnett et al., 2012). However, EGFR is
not synthesized as a pro-receptor that requires cleavage to the mature
form in the ER, suggesting that PCSK5 may have diverse
contributions to the function of receptor tyrosine kinase signaling
networks and that ‘upstream’ targeting of IGF-1R and EGFR
maturation through blockade of protein convertases is an exciting
area for future investigation. Our data suggest that PCSK5a, in the
absence of other co-expressed protein convertases, would be a
rationale target for blocking IGF-1R maturation and function.
Our work indicates that the effects of abnormal glycosylation on
INSR and IGF-1R are driven largely by abnormal convertase
glycosylation, a distinct and previously unrecognized mechanism
for receptor tyrosine kinase regulation by the OST. In addition, the
blockade of IGF-1R processing by small-molecule inhibition of the
OST with NGI-1 suggests that tumor therapy strategies that disrupt
N-linked glycosylation could potently reduce IGF-1R signaling. In
light of its effects on key oncogenic receptors, NGI-1 represents an
attractive cancer chemotherapeutic candidate.
In summary, we demonstrate that selective blockade of
N-glycosylation in STT3A-null cells reduces the maturation and cell
surface localization of two receptor tyrosine kinases, INSR and
IGF-1R. We also uncover PCSK5a as a substrate for STT3A and
show that loss of glycosylation on this convertase reduces its activity
and ability to rescue receptor processing when introduced into
STT3A-null cells. This work further highlights the ability of chemical
biology approaches such as SEEL to foster the identification of
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sensitive glycoproteins in the context of CDGs and elucidate the
functional consequences of modulating N-linked glycosylation.
MATERIALS AND METHODS
Reagents
Recombinant rat α-(2,6)-sialyltransferase (ST6Gal1) was prepared as
published previously (Meng et al., 2013). Biotinylated CMP-sialic acid
was synthesized as previously reported (Sun et al., 2016). Vibrio cholerae
neuraminidase (type II) (N6514) and Protein G Sepharose Fast Flow Beads
(P3296) were purchased from Sigma-Aldrich. FastAP Thermosensitive
Alkaline Phosphatase (EF0651), Protease Inhibitor Mini Tablets (88666)
and compatible Silver Stain for Mass Spectrometry (24600) were purchased
from Thermo Scientific. IgG fraction monoclonal mouse anti-biotin with
and without HRP conjugation were purchased from Jackson
ImmunoResearch Laboratories (200-032-211 and 200-002-011, 1:1000).
Rabbit anti-IGF-1R-receptor β (Cell Signaling Technology, 9750, 1:250),
rabbit anti-INSR β (Cell Signaling Technology, 3025, 1:1000), rabbit anti-
furin (PA1-062) and rabbit anti-ERp29 (both Thermo Fisher Scientific,
1:1000), mouse anti-β-actin (Abcam, ab20272, 1:2000), rabbit anti-Met
(Cell Signaling Technology, D1C2, 1:1000), mouse anti-calnexin (Thermo
Fisher, AF18, cat. # MA3-027, 1:1000), mouse anti-ERGIC-53 (Axxora,
ALX-804-602, 1:200) and rabbit anti-Flag (Sigma-Aldrich, F7425, 1:1000)
were used. Fluorophore or HRP-conjugated anti-mouse or anti-rabbit
secondary antibodies were used as appropriate for the corresponding
primary antibody. HRP-labeled secondary antibodies were purchased from
GE Healthcare. Goat anti-Myc was from Santa Cruz Biotechnology.
Fluorescent secondaries used were purchased from Invitrogen Molecular
Probes (Thermo Fisher Scientific). NGI-1 was prepared as previously
described (Lopez-Sambrooks et al., 2016).
Cell culture and transfections
STT3A-null (ΔA) and STT3B-null (ΔB) HEK293 cells were generated using
the CRISPR/Cas9 genome-editing system as described (Cherepanova and
Gilmore, 2016). Cells were cultured in 10 cm2 dishes at 37°C in DMEM
with 4.5 g/l L-glutamine (Lonza, 12-604F), containing 10% fetal bovine
serum (VWR, 1500-500), penicillin (100 IU/ml) and streptomycin
(100 μg/ml) (Corning, 30-001-CI). LoVo human colon carcinoma cells
were cultured in Ham’s F12 medium with L-glutamine (Lonza, 12-615F),
containing 10% fetal bovine serum (VWR, 1500-500), penicillin
(100 IU/ml) and streptomycin (100 μg/ml) (Corning, 30-001-CI). Cells
were transiently transfected with murine Flag-tagged Furin (Origene,
MR210693) or Flag-tagged PCSK5 (Origene, MR222003) using
Lipofectamine™ 2000 Transfection Reagent (Thermo Fisher, 11668030).
Cells were collected 48 h after transfection.
One-step SEEL labeling and proteomics
For labeling, cells were dissociated from the dish using Dulbecco’s
phosphate-buffered saline (DPBS) and transferred to Eppendorf tubes. Cell
surface labeling was performed in serum-free DMEM with 42 μg/ml
ST6Gal1, 34 μMCPM-Sia-C5-biotin, 13.3 μg/ml BSA, 13.3 μg/ml alkaline
phosphatase and 2 μl Arthrobacter ureafaciens (AU) neuraminidase per
reaction, with a reaction volume of 350 μl per tube for 2 h at 37°C. Lysis of
labeled cells was done using RIPA buffer, followed by immunoprecipitation
of 1 mg lysate using anti-biotin antibody. SDS-PAGE was done, followed
by silver stain and in-gel digestion of proteins, as described previously (Sun
et al., 2016). The resulting spectral count datawere normalized bymolecular
mass and the average fold change (shown in log2 values) was calculated for
the two replicates. Heat maps are shown for those that changed by more
than 2-fold (log2 values <−1 or >+1) in STT3A- or STT3B-null cells. The
comparative values for NGI-1-treated cells is also shown. In cases such as
INSR, where no counts were detected in one sample, we assigned that
protein a single spectral count in order to provide an estimated abundance.
Western blotting and immunoprecipitation
Cells were washed with DPBS and then lysed on ice in RIPA buffer (50 mM
Tris pH 8.0, 150 mM NaCl, 1% NP40, 0.1% SDS, 0.5% sodium
deoxycholate) supplemented with protease inhibitor mixture. Protein
concentrations were determined using the Micro BCA Protein Assay Kit
(Thermo Scientific). Biotin immunoprecipitation with protein G beads was
performed as reported previously (Yu et al., 2016). Proteins were separated
by SDS-PAGE and transferred to 0.45 μm nitrocellulose membranes.
Immunoreactive bands were identified with Clarity Western ECL substrate
(Bio-Rad) and imaged and quantified using the Bio-Rad ChemiDoc MP
Imaging System and Bio-Rad Image Lab software.
IGF-1R stimulation
Cells were plated for 48 h prior to incubation with various doses of
recombinant IGF-1 (source) for 2 h. Following activation, cells were washed
with DPBS and then cells lysed on ice in RIPA buffer (50 mM Tris pH 8.0,
150 mM NaCl, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate)
supplemented with protease inhibitor mixture and phosphatase inhibitors.
Lysates were resolved by SDS-PAGE as described above and western blot
analysis performed using an anti-phospho-IGF-1R antibody (Cell Signaling).
Quantitative RT-PCR (qRT-PCR)
For total RNA isolation, the Qiagen RNeasy Plus Kit (74134) was used.
cDNA synthesis was performed using the qScript cDNA synthesis kit with
500 ng RNA input (Quanta Biosciences, 95161). qRT-PCRs were
performed using PerfeCTa SYBR Green FastMix (Quanta, 95072-250) on
a Q-Tower3 (Analytik Jena) and data analysis was done using qPCRSoft 3.2
software. cDNAwas checked for genomic DNA (gDNA) contamination by
including control samples without reverse transcription. Ribosomal protein
L4 (rpl4) was used as a normalization control.
PCSK activity assay
PCSKactivitywas determinedusing aBoc-RVRR-AMCfluorogenic substrate
(Enzo, ALX-260-040). The assay was optimized and fluorescent activity
measured at Ex 360-380 nm, Em: 440-460 nm 60 min after addition of
substrate. Substrate specificity was confirmed by addition of a PCSK inhibitor
(Enzo, ALX-260-022), which completely blocked fluorescent activity.
Confocal immunofluorescence microscopy
HEKWT, HEK STT3A-null, HEK STT3B-null and LoVo cells were plated on
coverslips. When transfections were done, cells were transfected 24 h after
plating and staining performed 48 h after transfection. For experimentswithout
transfection, staining was done 24 h after plating. Immunofluorescence
staining was performed according to the manufacturer’s instructions (Cell
Signaling Technology). Images were acquired on an Olympus FV1000 laser-
scanning microscope outfitted with a 60× oil objective.
Site-directed mutagenesis
Mutagenesis of PCSK5 and furin N-glycosylation sites was done using the
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies).
Primers were designed to change Asn (N) sites to Gln (Q) according to kit
instructions. A list of primers used can be found in Table S1. Site-directed
mutagenesis by PCR was done according the manufacturer’s protocol and
mutagenesis confirmed by sequence analysis.
Statistical analyses
Results are expressed as mean±s.e.m. Statistical analyses were performed
using Graphpad Prism software. For paired comparisons of two groups, a
paired samples t-test was performed (Fig. 6B,D). For other parametric data, a
one-way ANOVA was performed, followed by Tukey’s (Fig. 4B) or
Dunnet’s multiple comparison tests (Figs 2B and 3A,B). A value of P<0.05
was considered statistically significant. *P<0.05, **P<0.01, ***P<0.001.
Pearson coefficients for the co-stains in Fig. 5B were calculated offline
using SlideBook™ Imaging Software (Intelligent Imaging Innovations).
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